Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth

Name: Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth
Start: 2026-12-01

December 1, 2026

Company: SELLAS Life Sciences Group, Inc. (SLS)
Drug: galinpepimut-s
Indication: Acute Myeloid Leukemia

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth — SLS Phase 3 Readout | BioSniper